All In Biotech

Drug Trial Radar · NCT01803360

Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.

A Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy of Neridronate 100 mg -4 i.v. Infusions- in Patients With Painful Osteoarthritis of the Knee With Bone Marrow Lesions.

Last checked: Nov 19, 2026Latest source record: Mar 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Jul 2013

Study completion Sep 2013

Sponsor

Lead sponsor
ASST Gaetano Pini-CTOAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether neridronate is effective in the treatment of pain related to bone marrow oedema in patients with osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

  • NeridronateDrug

    Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. knee pain reductionTime frame: 60 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istituto Ortopedico Gaetano Pini

    Milan, MI, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.